The former Bristol-Myers Squibb Medical Imaging unit announced it has changed its name to Lantheus Medical Imaging. With the new moniker comes a new management team, in addition to the launch of a new Web site,

The changes stem from Avista Capital Partners’ acquisition of the business this past January.

As recently appointed president and CEO of Lantheus, Don Kiepert said Lantheus is “well-positioned for growth with a market-leading product portfolio, promising pipeline, and a world-class organization committed to the field of medical imaging.”

The business will continue to provide medical imaging products for nuclear and ultrasound cardiovascular diagnostic imaging procedures, including Cardiolite (a kit for the preparation of technetium Tc99m sestamibi for injection), DEFINITY vial for (perflutren lipid microsphere) injectable suspension and TechneLite (technetium Tc99m generator).